Most health-conscious people already know about the broad-spectrum benefits of omega-3 fatty acids, particularly EPA/DHA from fish and other sources.
The typical American diet, however, contains too much omega-6 fatty acids. Health-conscious individuals try to reduce this type of fat in their diet. Sources of excess omega-6s include most vegetable oils such as corn oil, safflower oil, soybean oil, as well as poultry and eggs.
There is one omega-6, however, called gamma linolenic acid (GLA) with an impressive set of disease-fighting powers. New research reveals this nutrient’s power to combat chronic inflammation, eczema, dermatitis, asthma, rheumatoid arthritis, atherosclerosis, diabetes, obesity—even cancer!1-8
Most people don’t obtain sufficient quantities of it owing to dietary deficiency, and also because the enzyme in the body governing its metabolism becomes less active with age.9
In this article, we uncover the latest research on gamma linolenic acid and provide compelling evidence for its ability to combat a range of chronic age-related disorders—alone and in combination with EPA/DHA.
GLA: An Anti-Inflammatory Essential Fat
GLA (gamma linolenic acid) is a plant-derived omega-6 most abundant in seeds of an Eastern flower known as borage.1,10,11 Although a member of the omega-6 family, it’s metabolized differently than other omega-6s.
Our modern Western diet is rife with omega-6 fats and generally deficient in omega-3 fats, a fatal imbalance that sets in motion the inflammatory processes implicated in most killer diseases of aging.12-14
The threat this poses to aging humans is compounded by the aging process itself.
Aging results in defects occurring in human enzymes responsible for producing anti-inflammatory molecules from dietary fats. The result is an increased risk for inflammatory conditions of all kinds. Supplemental GLA can counteract this acquired enzyme defect, supplying vital biochemical precursors with powerful anti-inflammatory effects.
By converting into beneficial prostaglandins (PGE1s), GLA compensates for this deficiency.15,16 The results can be a profound reduction in the impact of inflammation on cardiovascular disease, lung function, autoimmune conditions, and metabolic abnormalities including diabetes.17-20
Another way GLA exerts a beneficial effect is to compete with harmful arachidonic acid or AA. When one eats foods like meat or egg yolk, excess levels of arachidonic acid accumulate that is then broken down into toxic byproducts by the enzymes cyclooxygenase-2 (COX-2) and lipoxygenase (LOX). GLA inhibits these destructive enzymes, thus impeding the ability of AA to convert to detrimental inflammatory molecules (like leukotriene B4).1
GLA plays an important role in modulating inflammation throughout the body, especially when incorporated into the membranes of immune system cells.18,21 Early in 2010, a team of Taiwanese researchers discovered that GLA regulates the inflammatory “master molecule” nuclear factor-kappaB or NF-kB, preventing it from switching on genes for inflammatory cytokines in cell nuclei.22
A separate mechanism by which GLA and other beneficial fatty acids reduce inflammation is by activating the powerful peroxisome proliferator-activated receptor (PPAR) system.23 PPARs are intracellular receptors that modulate cell metabolism and responses to inflammation. The class of antidiabetic drugs called thiazolidinediones (such as Actos® or pioglitazone) acts by targeting PPARs—but unlike GLA, they can be deadly.24
Novel Cardiac Defense
Atherosclerosis is in large part the result of chronic, low-grade inflammation.25 The GLA-producing enzyme delta 6-desaturase (D6D) declines with advancing age and stress. Some experts believe that this may both partially explain the age-related increase in atherosclerosis and indicate GLA as an attractive intervention to reduce arterial disease risk by bypassing this enzymatic defect.26 When incorporated into membranes of platelets, white blood cells, and endothelial cells, GLA works via multiple mechanisms to shift the cardiovascular system back towards its natural, non-inflamed state.27
In both human and animal studies, GLA reduces the tendency of platelets to aggregate, or clump together, within small blood vessels.28,29 This activity is related to its effect of reducing activity of thromboxane, a signaling molecule involved in blood clotting, and may be helpful in reducing the risk of heart attack and strokes.19,29 Laboratory research shows that cholesterol-induced stimulation of platelet aggregation, for example, is prevented with the addition of GLA.5
GLA also shows promise in lowering low-density lipoprotein (LDL) and triglyceride levels, while increasing high-density lipoprotein (HDL) concentration.5,19 GLA supplementation reduced the formation of atherosclerotic plaques in rats fed a high-cholesterol diet, reducing total cholesterol and triglycerides and dramatically inhibiting oxidation of LDL, an important first step in atherosclerosis.30
In the middle stages of atherosclerosis, smooth muscle cells in vessel walls proliferate, stiffening arteries and making them less responsive to blood pressure and flow. Cells from animals supplemented with GLA inhibit that smooth muscle proliferation.31 And in atherosclerosis-prone mice, GLA supplementation markedly suppressed proliferation in the aorta, while reducing the size of atherosclerotic lesions.32
These combined, multitargeted effects account for GLA’s promise in combating systemic vascular disease. In combination with EPA, GLA has significantly reduced blood pressure in patients with peripheral arterial disease, a painful and potentially crippling set of conditions resulting from restricted blood flow in the extremities. The combination of GLA and EPA also produced a trend towards fewer coronary events.33
A diet containing a balanced mixture of omega-3s (EPA and DHA) plus GLA was able to lower blood pressure in spontaneously hypertensive rats, while simultaneously enhancing antioxidant status, diminishing platelet aggregation, and lowering plasma lipids.34
Combating Diabetes and Obesity
New research reveals a surprising link between GLA and diabetes.
A defect in the enzyme that converts dietary fatty acids to GLA may predispose people to develop insulin resistance (“pre-diabetes”), suggesting that GLA supplementation may be preventive.7 Rapidly accumulating data support this observation.
Animal studies reveal that GLA can prevent chemically-induced diabetes while restoring normal antioxidant status in tissues.35 It can also prevent diabetic neuropathy, a painful condition resulting from exposure of nerves to high glucose levels.36 Excitingly, treatment with GLA plus alpha-lipoic acid (ALA) in diabetic rats not only prevents diabetes-induced changes in certain kinds of nerve cells—it partially reverses the condition.37
In humans, GLA supplements (360 mg per day) for six months significantly improved symptoms of diabetic neuropathy; nerve conduction velocity was also dramatically increased.38,39 These effects are most prominent in individuals whose diabetes is well-controlled.40
Children with type 1 diabetes display evidence of increased inflammation at an early age; GLA produces significant reductions in the inflammatory prostaglandin PGE2 after 8 months.41 Adult diabetics supplemented with GLA, EPA, DHA, and vitamin E experienced an improvement in metabolism of platelet-activating thromboxanes, which may reduce the risk of diabetic cardiovascular complications.42
Obesity is a risk factor for diabetes, and worsens diabetic complications by contributing massive amounts of inflammatory mediators. A fascinating study from the University of California at Davis found that, in formerly obese people who had recently achieved major weight loss, GLA supplementation for one year slashed the amount of weight they regained (just under 5 pounds vs. more than 19 pounds in control patients).6
Potent Anticancer Intervention
As early as 1989, it was revealed that GLA could slow the growth of certain cancer cells in culture.43 A blend of omega-3s (EPA and DHA) plus GLA reduced levels of a host of inflammatory cytokines in patients with colon cancer, one of the many cancers that rely on inflammation to stimulate their growth.44
In pre-clinical models, prostate cancer growth was slowed with GLA as a result of reduced production of inflammatory prostaglandins.45 Growth of a human lung cancer implanted in mice was inhibited by 56% while the animals were on a GLA-enriched diet.46 Cell cultures of three human tumor lines completely stopped DNA synthesis (a requirement for continued growth) after GLA treatment.47 GLA increases brain cancer cells’ sensitivity to being killed by radiation treatments; the supplement also produced direct toxicity to cancer cells, but not to normal tissue.48-50 This could mean greater effectiveness of radiation treatment with fewer distressing side effects such as skin damage.51
Human results with GLA supplementation have been encouraging. Patients with pancreatic cancer, a malignancy with a uniformly dismal prognosis, experienced longer survival times after intravenous treatment with a lithium salt of GLA.8 These changes were shown to be related to a GLA-induced increase in blood flow to cancerous tissue, which may permit larger doses of chemotherapy to reach tumors.52
GLA treatment in breast cancer has had remarkable results, now being included along with tamoxifen as an adjuvant therapy.53 And certain kinds of human leukemia cells can be induced to die by GLA treatment, which turns on the cells’ “suicide” enzymes.54 Leukemia cells resistant to chemotherapy drugs become vulnerable to drug treatment following exposure to GLA, which changes expression of several genes and causes the drugs to accumulate in high levels in the diseased cells.55
We now know that GLA inhibits tumor growth and spread through a host of interrelated mechanisms.56 As is always the case, however, the evidence suggests that GLA supplementation is much more effective used as prevention than as treatment after cancer has developed.57,58
Eliminating Eczema and Atopic Dermatitis
Eczema is an inflammatory skin condition characterized by dryness and flaking of the upper skin layers, with redness, itching, and often pain of the skin beneath. Mild in many people, severe eczema sufferers experience chronic misery that can be debilitating, and that may respond only to fairly large doses of steroids, which can produce dangerous side effects. Many people with eczema also suffer from asthma and other conditions related to allergic responses—together these conditions are referred to as atopic conditions, which involve an immune response within the body. As with asthma, the global incidence of atopic eczema is rising at an alarming rate.59
Studies from 20 years ago first showed that people with eczema may have a defect in their bodies that inhibits their ability to form GLA naturally from the dietary source linoleic acid.2,60 Breast milk from mothers of children with newly developed atopic eczema was shown to have low levels of GLA and its metabolites, supporting this notion.61
Supplementation with GLA was immediately successful. Studies in both children and adults revealed less inflammation, dryness, scaling, and overall eczematic severity compared to controls.2,62,63
In parallel with these beneficial changes, significant changes in plasma fatty acid composition were also noted.2,63 Subsequent analyses showed that there was a positive correlation between improvements in clinical eczema scores and the rise in beneficial fatty acid levels.64 In addition, GLA supplementation produced an increase in the immune system “suppressor” cells known as CD8, adding another layer of protection against inflammation.65
A Natural Asthma Intervention
Asthma is closely related to eczema in being an inflammatory condition triggered by inflammatory cytokines, particularly leukotrienes.66 Inhibitors of leukotrienes and their receptors are in widespread use in asthma management, and since GLA suppresses leukotriene production, it is natural to wonder whether GLA would be helpful in asthma as well.21,66
In a placebo-controlled trial, daily consumption of 750-1,130 mg GLA plus 500-750 mg eicosapentaenoic acid (EPA) improved self-reported asthma status and reduced reliance on “rescue” inhaler drugs in adults with mild-to-moderate asthma.3 A related study also demonstrated an improved asthma-related quality of life following supplementation.67
Rheumatoid Arthritis Relief
GLA shows great promise in managing symptoms of autoimmune conditions such as rheumatoid arthritis (RA) and may prove an attractive alternative to potentially toxic nonsteroidal anti-inflammatory drugs (NSAIDs).68,69 In randomized, placebo-controlled studies of RA patients with active symptoms, treatment with GLA (1,400-2,800 mg per day) reduced the number of tender and swollen joints and lowered pain and tenderness scores.4,70
Laboratory research reveals that GLA treatment of immune cells from RA patients decreases production of the inflammatory cytokine IL-1beta by about 40% while leaving normal immune function of the cells intact;71 this finding has also been demonstrated in human research.72 GLA from borage oil triggers a pathway that suppresses a different inflammatory cytokine, TNF-alpha.73 Experts have concluded that “Strong support exists for gamma linolenic acid (GLA) for pain of rheumatoid arthritis.”74 Their findings suggested doses of at least 1,400 mg per day for good results.14
Summary
Gamma linolenic acid or GLA is an omega-6 essential fatty acid with overlooked potent benefits for human health. Because of an age-related decline in activity of enzymes that naturally produce GLA from precursor fats in our diet, we risk developing GLA deficiency with age. Too little GLA tips the balance of inflammatory factors called cytokines in our bodies towards increasing inflammation, and with it increasing risk for chronic disease. GLA supplementation can overcome this deficiency, providing the anti-inflammatory stimulus we need to control and even prevent diseases such as eczema, asthma, rheumatoid arthritis, and major killers such as cardiovascular disease and cancer.
If you have any questions on the scientific content of this article, please call a Life Extension® Health Advisor at
1-866-864-3027. |
| References |
1. Belch JJ, Hill A. Evening primrose oil and borage oil in rheumatologic conditions. Am J Clin Nutr. 2000 Jan;71(1 Suppl):352S-6S.
2. Bordoni A, Biagi PL, Masi M, et al. Evening primrose oil (Efamol) in the treatment of children with atopic eczema. Drugs Exp Clin Res. 1988;14(4):291-7.
3. Surette ME, Stull D, Lindemann J. The impact of a medical food containing gammalinolenic and eicosapentaenoic acids on asthma management and the quality of life of adult asthma patients. Curr Med Res Opin. 2008 Feb;24(2):559-67.
4. Leventhal LJ, Boyce EG, Zurier RB. Treatment of rheumatoid arthritis with gammalinolenic acid. Ann Intern Med. 1993 Nov 1;119(9):867-73.
5. Ishikawa T, Fujiyama Y, Igarashi O, et al. Effects of gammalinolenic acid on plasma lipoproteins and apolipoproteins. Atherosclerosis. 1989 Feb;75(2-3):95-104.
6. Schirmer MA, Phinney SD. Gamma-linolenate reduces weight regain in formerly obese humans. J Nutr. 2007 Jun;137(6):1430-5.
7. Das UN. A defect in the activity of Delta6 and Delta5 desaturases may be a factor predisposing to the development of insulin resistance syndrome. Prostaglandins Leukot Essent Fatty Acids. 2005 May;72(5):343-50.
8. Fearon KC, Falconer JS, Ross JA, et al. An open-label phase I/II dose escalation study of the treatment of pancreatic cancer using lithium gammalinolenate. Anticancer Res. 1996 Mar-Apr;16(2):867-74.
9. Li MC, Sun Y, Zhang Q, Xing LJ. Expression of delta6-fatty acid desaturase gene from Mortierella alpina in Pichia pastoris. Sheng Wu Gong Cheng Xue Bao. 2004 Jan;20(1):34-8.
10. Henz BM, Jablonska S, van de Kerkhof PC, et al. Double-blind, multicentre analysis of the efficacy of borage oil in patients with atopic eczema. Br J Dermatol. 1999 Apr;140(4):685-8.
11. Cameron M, Gagnier JJ, Little CV, Parsons TJ, Blumle A, Chrubasik S. Evidence of effectiveness of herbal medicinal products in the treatment of arthritis. Part 2: Rheumatoid arthritis. Phytother Res. 2009 Dec;23(12):1647-62.
12. Chilton FH, Rudel LL, Parks JS, Arm JP, Seeds MC. Mechanisms by which botanical lipids affect inflammatory disorders. Am J Clin Nutr. 2008 Feb;87(2):498S-503S.
13. Simopoulos AP. The omega-6/omega-3 fatty acid ratio, genetic variation, and cardiovascular disease. Asia Pac J Clin Nutr. 2008;17 Suppl 1:131-4.
14. Simopoulos AP. Evolutionary aspects of diet and essential fatty acids. World Rev Nutr Diet. 2001;88:18-27.
15. Fan YY, Chapkin RS. Importance of dietary gamma-linolenic acid in human health and nutrition. J Nutr. 1998 Sep;128(9):1411-4.
16. Stone KJ, Willis AL, Hart WM, Kirtland SJ, Kernoff PB, McNicol GP. The metabolism of dihomo-gamma-linolenic acid in man. Lipids. 1979 Feb;14(2):174-80.
17. Kapoor R, Huang YS. Gamma linolenic acid: an antiinflammatory omega-6 fatty acid. Curr Pharm Biotechnol. 2006 Dec;7(6):531-4.
18. Johnson MM, Swan DD, Surette ME, et al. Dietary supplementation with gamma-linolenic acid alters fatty acid content and eicosanoid production in healthy humans. J Nutr. 1997 Aug;127(8):1435-44.
19. Guivernau M, Meza N, Barja P, Roman O. Clinical and experimental study on the long-term effect of dietary gamma-linolenic acid on plasma lipids, platelet aggregation, thromboxane formation, and prostacyclin production. Prostaglandins Leukot Essent Fatty Acids. 1994 Nov;51(5):311-6.
20. Dobryniewski J, Szajda SD, Waszkiewicz N, Zwierz K. The gamma-linolenic acid (GLA)—the therapeutic value. Przegl Lek. 2007;64(2):100-2.
21. Ziboh VA, Naguwa S, Vang K, et al. Suppression of leukotriene B4 generation by ex-vivo neutrophils isolated from asthma patients on dietary supplementation with gammalinolenic acid-containing borage oil: possible implication in asthma. Clin Dev Immunol. 2004 Mar;11(1):13-21.
22. Chang CS, Sun HL, Lii CK, Chen HW, Chen PY, Liu KL. Gamma-linolenic acid inhibits inflammatory responses by regulating NF-kappaB and AP-1 activation in lipopolysaccharide-induced RAW 264.7 macrophages. Inflammation. 2010 Feb;33(1):46-57.
23. Hontecillas R, O’Shea M, Einerhand A, Diguardo M, Bassaganya-Riera J. Activation of PPAR gamma and alpha by punicic acid ameliorates glucose tolerance and suppresses obesity-related inflammation. J Am Coll Nutr. 2009 Apr;28(2):184-95.
24. Chaggar PS, Shaw SM, Williams SG. Review article: Thiazolidinediones and heart failure. Diab Vasc Dis Res. 2009 Jul;6(3):146-52.
25. Das UN. Can essential fatty acids reduce the burden of disease(s)? Lipids Health Dis. 2008;7:9.
26. Das UN. A defect in the activity of Delta6 and Delta5 desaturases may be a factor in the initiation and progression of atherosclerosis. Prostaglandins Leukot Essent Fatty Acids. 2007 May;76(5):251-68.
27. Das UN. Essential fatty acids and their metabolites could function as endogenous HMG-CoA reductase and ACE enzyme inhibitors, anti-arrhythmic, anti-hypertensive, anti-atherosclerotic, anti-inflammatory, cytoprotective, and cardioprotective molecules. Lipids Health Dis. 2008;7:37.
28. Belch JJ, Shaw B, O’Dowd A, et al. Evening primrose oil (Efamol) in the treatment of Raynaud’s phenomenon: a double blind study. Thromb Haemost. 1985 Aug 30;54(2):490-4.
29. Riaz A, Khan RA, Ahmed SP. Assessment of anticoagulant effect of evening primrose oil. Pak J Pharm Sci. 2009 Oct;22(4):355-9.
30. Shi LM, Ge HT, Kong XQ, et al. Effects of gamma linolenic acid on atherosclerosis induced by cholesterol-rich diet in rats. Zhongguo Zhong Yao Za Zhi. 2008 Dec;33(23):2808-12.
31. Fan YY, Ramos KS, Chapkin RS. Modulation of atherogenesis by dietary gamma-linolenic acid. Adv Exp Med Biol. 1999;469:485-91.
32. Fan YY, Ramos KS, Chapkin RS. Dietary gamma-linolenic acid suppresses aortic smooth muscle cell proliferation and modifies atherosclerotic lesions in apolipoprotein E knockout mice. J Nutr. 2001 Jun;131(6):1675-81.
33. Leng GC, Lee AJ, Fowkes FG, et al. Randomized controlled trial of gamma-linolenic acid and eicosapentaenoic acid in peripheral arterial disease. Clin Nutr. 1998 Dec;17(6):265-71.
34. Frenoux JM, Prost ED, Belleville JL, Prost JL. A polyunsaturated fatty acid diet lowers blood pressure and improves antioxidant status in spontaneously hypertensive rats. J Nutr. 2001 Jan;131(1):39-45.
35. Suresh Y, Das UN. Long-chain polyunsaturated fatty acids and chemically induced diabetes mellitus: effect of omega-6 fatty acids. Nutrition. 2003 Feb;19(2):93-114.
36. Pitel S, Raccah D, Gerbi A, Pieroni G, Vague P, Coste TC. At low doses, a gamma-linolenic acid-lipoic acid conjugate is more effective than docosahexaenoic acid-enriched phospholipids in preventing neuropathy in diabetic rats. J Nutr. 2007 Feb;137(2):368-72.
37. Shotton HR, Broadbent S, Lincoln J. Prevention and partial reversal of diabetes-induced changes in enteric nerves of the rat ileum by combined treatment with alpha-lipoic acid and evening primrose oil. Auton Neurosci. 2004 Mar 31;111(1):57-65.
38. Jamal GA, Carmichael H. The effect of gamma-linolenic acid on human diabetic peripheral neuropathy: a double-blind placebo-controlled trial. Diabet Med. 1990 May;7(4):319-23.
39. Horrobin DF. Essential fatty acids in the management of impaired nerve function in diabetes. Diabetes. 1997 Sep;46 Suppl 2:S90-3.
40. Keen H, Payan J, Allawi J, et al. Treatment of diabetic neuropathy with gamma-linolenic acid. The gamma-Linolenic Acid Multicenter Trial Group. Diabetes Care. 1993 Jan;16(1):8-15.
41. Arisaka M, Arisaka O, Yamashiro Y. Fatty acid and prostaglandin metabolism in children with diabetes mellitus. II. The effect of evening primrose oil supplementation on serum fatty acid and plasma prostaglandin levels. Prostaglandins Leukot Essent Fatty Acids. 1991 Jul;43(3):197-201.
42. Takahashi R, Inoue J, Ito H, Hibino H. Evening primrose oil and fish oil in non-insulin-dependent-diabetes. Prostaglandins Leukot Essent Fatty Acids. 1993 Aug;49(2):569-71.
43. Botha JH, Robinson KM, Ramchurren N, Norman RJ. The role of prostaglandins in the inhibition of cultured carcinoma cell growth produced by gamma-linolenic acid. Prostaglandins Leukot Essent Fatty Acids. 1989 Feb;35(2):119-23.
44. Purasiri P, Murray A, Richardson S, Heys SD, Horrobin D, Eremin O. Modulation of cytokine production in vivo by dietary essential fatty acids in patients with colorectal cancer. Clin Sci (Lond). 1994 Dec;87(6):711-7.
45. Pham H, Vang K, Ziboh VA. Dietary gamma-linolenate attenuates tumor growth in a rodent model of prostatic adenocarcinoma via suppression of elevated generation of PGE(2) and 5S-HETE. Prostaglandins Leukot Essent Fatty Acids. 2006 Apr;74(4):271-82.
46. de Bravo MG, Tournier H, Schinella G, Viaggi M, Quintans C. Effect of dietary supplementation with gamma-linolenic acid on the growth of a human lung carcinoma implanted in nude mice. Medicina (B Aires). 1995;55(6):670-4.
47. Hrelia S, Bordoni A, Biagi P, et al. gamma-Linolenic acid supplementation can affect cancer cell proliferation via modification of fatty acid composition. Biochem Biophys Res Commun. 1996 Aug 14;225(2):441-7.
48. Vartak S, Robbins ME, Spector AA. Polyunsaturated fatty acids increase the sensitivity of 36B10 rat astrocytoma cells to radiation-induced cell kill. Lipids. 1997 Mar;32(3):283-92.
49. Vartak S, McCaw R, Davis CS, Robbins ME, Spector AA. Gamma-linolenic acid (GLA) is cytotoxic to 36B10 malignant rat astrocytoma cells but not to ‘normal’ rat astrocytes. Br J Cancer. 1998 May;77(10):1612-20.
50. Das UN. Gamma-linolenic acid therapy of human glioma-a review of in vitro, in vivo, and clinical studies. Med Sci Monit. 2007 Jul;13(7):RA119-31.
51. Rahbeeni F, Hendrikse AS, Smuts CM, Gelderblom WC, Abel S, Blekkenhorst GH. The effect of evening primrose oil on the radiation response and blood flow of mouse normal and tumour tissue. Int J Radiat Biol. 2000 Jun;76(6):871-7.
52. Kairemo KJ, Jekunen AP, Korppi-Tommola ET, Pyrhonen SO. Effects of lithium gammalinolenate on the perfusion of liver and pancreatic tissues in pancreatic cancer. Anticancer Res. 1997 Sep-Oct;17(5B):3729-36.
53. Kenny FS, Pinder SE, Ellis IO, et al. Gamma linolenic acid with tamoxifen as primary therapy in breast cancer. Int J Cancer. 2000 Mar 1;85(5):643-8.
54. Ge H, Kong X, Shi L, Hou L, Liu Z, Li P. Gamma-linolenic acid induces apoptosis and lipid peroxidation in human chronic myelogenous leukemia K562 cells. Cell Biol Int. 2009 Mar;33(3):402-10.
55. Kong X, Ge H, Chen L, et al. Gamma-linolenic acid modulates the response of multidrug-resistant K562 leukemic cells to anticancer drugs. Toxicol In Vitro. 2009 Jun;23(4):634-9.
56. Miyake JA, Benadiba M, Colquhoun A. Gamma-linolenic acid inhibits both tumour cell cycle progression and angiogenesis in the orthotopic C6 glioma model through changes in VEGF, Flt1, ERK1/2, MMP2, cyclin D1, pRb, p53 and p27 protein expression. Lipids Health Dis. 2009;8:8.
57. Das UN. Nutrients, essential fatty acids and prostaglandins interact to augment immune responses and prevent genetic damage and cancer. Nutrition. 1989 Mar-Apr;5(2):106-10.
58. Booyens J, Maguire L, Katzeff IE. Dietary fats and cancer. Med Hypotheses. 1985 Aug;17(4):351-62.
59. Morse NL, Clough PM. A meta-analysis of randomized, placebo-controlled clinical trials of Efamol evening primrose oil in atopic eczema. Where do we go from here in light of more recent discoveries? Curr Pharm Biotechnol. 2006 Dec;7(6):503-24.
60. Kerscher MJ, Korting HC. Treatment of atopic eczema with evening primrose oil: rationale and clinical results. Clin Investig. 1992 Feb;70(2):167-71.
61. Businco L, Ioppi M, Morse NL, Nisini R, Wright S. Breast milk from mothers of children with newly developed atopic eczema has low levels of long chain polyunsaturated fatty acids. J Allergy Clin Immunol. 1993 Jun;91(6):1134-9.
62. Biagi PL, Bordoni A, Masi M, et al. A long-term study on the use of evening primrose oil (Efamol) in atopic children. Drugs Exp Clin Res. 1988;14(4):285-90.
63. Schalin-Karrila M, Mattila L, Jansen CT, Uotila P. Evening primrose oil in the treatment of atopic eczema: effect on clinical status, plasma phospholipid fatty acids and circulating blood prostaglandins. Br J Dermatol. 1987 Jul;117(1):11-9.
64. Morse PF, Horrobin DF, Manku MS, et al. Meta-analysis of placebo-controlled studies of the efficacy of Epogam in the treatment of atopic eczema. Relationship between plasma essential fatty acid changes and clinical response. Br J Dermatol. 1989 Jul;121(1):75-90.
65. Fiocchi A, Sala M, Signoroni P, Banderali G, Agostoni C, Riva E. The efficacy and safety of gamma-linolenic acid in the treatment of infantile atopic dermatitis. J Int Med Res. 1994 Jan-Feb;22(1):24-32.
66. Surette ME, Koumenis IL, Edens MB, et al. Inhibition of leukotriene biosynthesis by a novel dietary fatty acid formulation in patients with atopic asthma: a randomized, placebo-controlled, parallel-group, prospective trial. Clin Ther. 2003 Mar;25(3):972-9.
67. Lindemann J, David Pampe E, Peterkin JJ, Orozco-Cronin P, Belofsky G, Stull D. Clinical study of the effects on asthma-related QOL and asthma management of a medical food in adult asthma patients. Curr Med Res Opin. 2009 Dec;25(12):2865-75.
68. Belch JJ, Ansell D, Madhok R, O’Dowd A, Sturrock RD. Effects of altering dietary essential fatty acids on requirements for non-steroidal anti-inflammatory drugs in patients with rheumatoid arthritis: a double blind placebo controlled study. Ann Rheum Dis. 1988 Feb;47(2):96-104.
69. Brzeski M, Madhok R, Capell HA. Evening primrose oil in patients with rheumatoid arthritis and side-effects of non-steroidal anti-inflammatory drugs. Br J Rheumatol. 1991 Oct;30(5):370-2.
70. Zurier RB, Rossetti RG, Jacobson EW, et al. gamma-Linolenic acid treatment of rheumatoid arthritis. A randomized, placebo-controlled trial. Arthritis Rheum. 1996 Nov;39(11):1808-17.
71. Furse RK, Rossetti RG, Zurier RB. Gammalinolenic acid, an unsaturated fatty acid with anti-inflammatory properties, blocks amplification of IL-1 beta production by human monocytes. J Immunol. 2001 Jul 1;167(1):490-6.
72. Furse RK, Rossetti RG, Seiler CM, Zurier RB. Oral administration of gammalinolenic acid, an unsaturated fatty acid with anti-inflammatory properties, modulates interleukin-1beta production by human monocytes. J Clin Immunol. 2002 Mar;22(2):83-91.
73. Kast RE. Borage oil reduction of rheumatoid arthritis activity may be mediated by increased cAMP that suppresses tumor necrosis factor-alpha. Int Immunopharmacol. 2001 Nov;1(12):2197-9.
74. Soeken KL. Selected CAM therapies for arthritis-related pain: the evidence from systematic reviews. Clin J Pain. 2004 Jan-Feb;20(1):13-8. |
|
